216 related articles for article (PubMed ID: 33327998)
21. A prospective evaluation of minimal residual disease as risk stratification for CCLG-ALL-2008 treatment protocol in pediatric B precursor acute lymphoblastic leukemia.
Hu YX; Lu J; He HL; Wang Y; Li JQ; Xiao PF; Li J; Lv H; Sun YN; Fan JJ; Chai YH; Hu SY
Eur Rev Med Pharmacol Sci; 2016 May; 20(9):1680-90. PubMed ID: 27212157
[TBL] [Abstract][Full Text] [Related]
22. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
[TBL] [Abstract][Full Text] [Related]
23. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of minimal residual disease in childhood acute myeloid leukemia.
Miyamura T; Sakata N; Okamura T; Yasui M; Inoue M; Yagi K; Sako M; Komada Y; Matsuyama T; Oda M; Park YD; Kawa K
Int J Hematol; 2004 Apr; 79(3):243-9. PubMed ID: 15168592
[TBL] [Abstract][Full Text] [Related]
25. Analysis of ETV6/AML1 abnormalities in acute lymphoblastic leukaemia: incidence, alternative spliced forms and minimal residual disease value.
Codrington R; O'Connor HE; Jalali GR; Carrara P; Papaioannou M; Hart SM; Hoffbrand AV; Potter M; Prentice HG; Harrison CJ; Foroni L
Br J Haematol; 2000 Dec; 111(4):1071-9. PubMed ID: 11167742
[TBL] [Abstract][Full Text] [Related]
26. [Clinical significance of monitoring ETV6-RUNX1 fusion gene expression in children with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Hong Y; Qin YZ; Xu YY; Zhou SH; Wang Y; Xu LP; Zhang XH; Huang XJ; Zhao XS
Zhonghua Xue Ye Xue Za Zhi; 2017 Aug; 38(8):680-684. PubMed ID: 28954346
[No Abstract] [Full Text] [Related]
27. Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.
Gupta SK; Bakhshi S; Chopra A; Kamal VK
Leuk Lymphoma; 2018 Aug; 59(8):1899-1904. PubMed ID: 29199525
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].
Mei YY; Gao C; Cui L; Zhao XX; Zhao W; Li WJ; Wang KL; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Li ZG
Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):467-71. PubMed ID: 24120066
[TBL] [Abstract][Full Text] [Related]
29. [Clinical features and prognosis of childhood B-lineage acute lymphoblastic leukemia expressing the
Zhang F; Lu AD; Zuo YX; Ding MM; Jia YP; Zhang LP
Zhongguo Dang Dai Er Ke Za Zhi; 2022 May; 24(5):543-549. PubMed ID: 35644195
[TBL] [Abstract][Full Text] [Related]
30. Real-world utility of early measurable residual disease assessments by multi-parametric flow cytometry in adult patients with B-lymphoblastic leukemia receiving Hyper-CVAD induction chemotherapy.
Nedumannil R; Ritchie D; Bajel A; Ng AP; Harrison SJ; Westerman D
Eur J Haematol; 2023 Feb; 110(2):168-176. PubMed ID: 36321745
[TBL] [Abstract][Full Text] [Related]
31. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Significance of CD20 Expression in Children with Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
Wang Y; Xue YJ; Jia YP; Zuo YX; Lu AD; Zhang LP
Acta Haematol; 2023; 146(5):349-357. PubMed ID: 37212472
[TBL] [Abstract][Full Text] [Related]
34. Low Frequency of ETV6-RUNX1 (t 12; 21) in Saudi Arabian Pediatric Acute Lymphoblastic Leukemia Patients: Association with Clinical Parameters and Early Remission.
Aljamaan K; Aljumah TK; Aloraibi S; Absar M; Iqbal Z
Asian Pac J Cancer Prev; 2015; 16(17):7523-7. PubMed ID: 26625756
[TBL] [Abstract][Full Text] [Related]
35. The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: A 10-year retrospective study.
Zhou B; Chu X; Tian H; Liu T; Liu H; Gao W; Chen S; Hu S; Wu D; Xu Y
Am J Hematol; 2021 Nov; 96(11):1461-1471. PubMed ID: 34406703
[TBL] [Abstract][Full Text] [Related]
36. Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia.
de Haas V; Oosten L; Dee R; Verhagen OJ; Kroes W; van den Berg H; van der Schoot CE
Br J Haematol; 2000 Dec; 111(4):1080-6. PubMed ID: 11167743
[TBL] [Abstract][Full Text] [Related]
37. BCR-ABL, ETV6-RUNX1 and E2A-PBX1: prevalence of the most common acute lymphoblastic leukemia fusion genes in Mexican patients.
Jiménez-Morales S; Miranda-Peralta E; Saldaña-Alvarez Y; Perez-Vera P; Paredes-Aguilera R; Rivera-Luna R; Velázquez-Cruz R; Ramírez-Bello J; Carnevale A; Orozco L
Leuk Res; 2008 Oct; 32(10):1518-22. PubMed ID: 18455790
[TBL] [Abstract][Full Text] [Related]
38. [Clinical Significance of Minimal Residual Disease in Risk Stratification and Prognosis of Childhood B-lineage Acute Lymphoblastic Leukemia].
An FY; Zhang SH; Kong LJ; Liang Y; Xu JX; He HL; Chai YH; Zhao WL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):729-735. PubMed ID: 28641626
[TBL] [Abstract][Full Text] [Related]
39. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
40. E2A-PBX1 exhibited a promising prognosis in pediatric acute lymphoblastic leukemia treated with the CCLG-ALL2008 protocol.
Hu Y; He H; Lu J; Wang Y; Xiao P; Li J; Li J; Sun Y; Lv H; Fan J; Yao Y; Chai Y; Hu S
Onco Targets Ther; 2016; 9():7219-7225. PubMed ID: 27920559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]